Main Menu


The Institute of Cancer Research currently has a number of partnering and licensing opportunities and any member of the Enterprise Unit would be pleased to review these with potential commercial collaborators.

HDAC9, a novel histone deacetylase

ICR collaboration and licensing opportunity.
Principal Scientists: Dr Arthur Zelent

Characterisation of a novel HDAC associated with cancer. Potential drug target and diagnostic marker.

For further information contact Paul Carnochan or download the PDF flyer.

Glypican-5, a novel cancer target

ICR collaboration and licensing opportunity.
Principal Scientists:  Dr Janet Shipley

GPC5 has been identified as a potential therapeutic target in soft tissue sarcoma, breast carcinoma, lung carcinoma, lymphoma, medulloblastoma and glioblastoma. This target is amenable to antibody mediated therapies. It also has potential as a biomarker.

For further information contact Jonathan Beech or download the PDF flyer.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.